HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chia-Yen Dai Selected Research

RNA (Ribonucleic Acid)

1/2022Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.
1/2022Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication.
1/2021Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals.
1/2021Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection.
1/2021Exosome-derived differentiation antagonizing non-protein coding RNA with risk of hepatitis C virus-related hepatocellular carcinoma recurrence.
1/2021Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues.
1/2021Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues.
12/2020Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication.
11/2020Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication.
11/2020Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Chia-Yen Dai Research Topics

Disease

108Chronic Hepatitis C
09/2022 - 01/2002
83Infections
08/2022 - 01/2002
50Fibrosis (Cirrhosis)
07/2022 - 03/2002
48Hepatocellular Carcinoma (Hepatoma)
04/2022 - 04/2005
27Chronic Hepatitis B
01/2022 - 02/2006
22Liver Cirrhosis (Hepatic Cirrhosis)
10/2021 - 03/2002
20Hepatitis B
07/2022 - 07/2010
20Hepatitis C
01/2022 - 02/2006
19Neoplasms (Cancer)
02/2022 - 03/2013
14Viremia
12/2021 - 01/2002
10Hepatitis
07/2022 - 06/2007
8Non-alcoholic Fatty Liver Disease
03/2022 - 03/2016
8Liver Diseases (Liver Disease)
10/2021 - 01/2007
6Body Weight (Weight, Body)
07/2022 - 02/2006
6Virus Diseases (Viral Diseases)
02/2022 - 07/2003
6Coinfection
10/2021 - 10/2004
5Chronic Renal Insufficiency
01/2022 - 07/2020
5Fatty Liver
12/2021 - 07/2015
5HIV Infections (HIV Infection)
07/2020 - 01/2014
5Insulin Resistance
05/2015 - 04/2009
4Hypertension (High Blood Pressure)
01/2022 - 09/2012
4Disease Progression
01/2022 - 06/2017
4Type 2 Diabetes Mellitus (MODY)
04/2021 - 02/2008
3Diabetes Mellitus
01/2022 - 09/2012
3Inflammation (Inflammations)
10/2021 - 04/2020
3Hearing Loss (Hearing Impairment)
04/2021 - 01/2016
3Cardiovascular Diseases (Cardiovascular Disease)
03/2021 - 08/2010
3Liver Neoplasms (Liver Cancer)
12/2016 - 07/2013
2Hyperlipidemias (Hyperlipidemia)
01/2022 - 01/2021
2Cryoglobulinemia
01/2022 - 11/2018
2Chronic Kidney Failure (Chronic Renal Failure)
08/2021 - 01/2021
2Hyperuricemia
03/2020 - 01/2018
2Substance-Related Disorders (Drug Abuse)
07/2017 - 11/2009

Drug/Important Bio-Agent (IBA)

52Ribavirin (Virazole)FDA LinkGeneric
01/2022 - 10/2004
51Antiviral Agents (Antivirals)IBA
09/2022 - 08/2009
40InterferonsIBA
01/2022 - 07/2003
34RNA (Ribonucleic Acid)IBA
01/2022 - 01/2002
21Hepatitis B Surface Antigens (HBsAg)FDA Link
12/2021 - 09/2003
16Interferon-alpha (Interferon Alfa)IBA
12/2015 - 01/2002
14Alanine Transaminase (SGPT)IBA
12/2021 - 01/2002
12DNA (Deoxyribonucleic Acid)IBA
12/2021 - 01/2002
11Glucose (Dextrose)FDA LinkGeneric
09/2022 - 02/2008
9Biomarkers (Surrogate Marker)IBA
04/2022 - 11/2007
9Triglycerides (Triacylglycerol)IBA
03/2021 - 07/2006
8Proteins (Proteins, Gene)FDA Link
03/2022 - 05/2011
7Hepatitis B e AntigensIBA
07/2022 - 12/2007
7Uric Acid (Urate)IBA
03/2020 - 09/2008
6LipidsIBA
03/2021 - 07/2008
6Fetal Proteins (Fetoprotein)IBA
03/2018 - 01/2014
6Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
09/2017 - 06/2003
6Lamivudine (Epivir)FDA Link
11/2016 - 12/2006
5Sorafenib (BAY 43-9006)FDA Link
02/2022 - 10/2019
5nasIBA
01/2022 - 01/2019
5NucleotidesIBA
01/2022 - 11/2020
5alpha-Fetoproteins (alpha-Fetoprotein)IBA
01/2022 - 02/2015
5micaIBA
01/2019 - 12/2015
4Aspartate Aminotransferases (Aspartate Transaminase)IBA
09/2022 - 01/2011
4Pharmaceutical PreparationsIBA
02/2022 - 01/2014
4CytokinesIBA
01/2022 - 03/2011
4BilirubinIBA
01/2022 - 10/2019
4NucleosidesIBA
01/2022 - 11/2020
4C-Reactive ProteinIBA
11/2021 - 03/2002
4CholesterolIBA
03/2016 - 07/2008
3wisteria lectinIBA
03/2022 - 08/2017
3Carrier Proteins (Binding Protein)IBA
03/2022 - 08/2017
3SofosbuvirIBA
02/2022 - 01/2021
3Transaminases (Aminotransferases)IBA
12/2021 - 06/2003
3Indicators and Reagents (Reagents)IBA
01/2021 - 03/2002
3MicroRNAs (MicroRNA)IBA
03/2016 - 05/2011
3Phospholipases (Phospholipase)IBA
03/2016 - 03/2015
3peginterferon alfa-2a (Pegasys)FDA Link
10/2015 - 07/2010
3Serum AlbuminIBA
01/2015 - 11/2007
2Ferritins (Ferritin)IBA
09/2022 - 02/2019
2Tenofovir (Viread)FDA Link
07/2022 - 12/2021
2TransferasesIBA
01/2022 - 07/2014
2entecavirFDA Link
12/2021 - 11/2016
2Transforming Growth Factors (Transforming Growth Factor)IBA
11/2021 - 04/2014
2Insulin (Novolin)FDA Link
10/2021 - 05/2015
2Heat-Shock Proteins (Heat-Shock Protein)IBA
04/2021 - 03/2008
2AlbuminsIBA
04/2021 - 12/2020
2asunaprevirIBA
01/2021 - 01/2020
2daclatasvirIBA
01/2021 - 01/2020
2AntigensIBA
06/2020 - 11/2016
2IronIBA
02/2019 - 01/2006
2InterleukinsIBA
03/2018 - 04/2013
2Beclin-1IBA
01/2018 - 11/2017
2Blood Glucose (Blood Sugar)IBA
12/2017 - 09/2012
2Lymphotoxin-alpha (Lymphotoxin)IBA
09/2017 - 07/2017
2AntibodiesIBA
07/2017 - 01/2014
2Peptides (Polypeptides)IBA
05/2017 - 12/2015
2Viral RNAIBA
10/2016 - 10/2016
2oxidized low density lipoproteinIBA
05/2015 - 05/2011

Therapy/Procedure

81Therapeutics
04/2022 - 01/2002
6Renal Dialysis (Hemodialysis)
08/2021 - 02/2002
4Drug Therapy (Chemotherapy)
02/2022 - 01/2019
3Aftercare (After-Treatment)
01/2021 - 07/2010
3Liver Transplantation
06/2018 - 01/2007
2Duration of Therapy
06/2020 - 06/2008
2Blood Transfusion (Blood Transfusions)
01/2018 - 01/2002
2Secondary Prevention
06/2017 - 12/2015